Publications:

• Design and Rationale of GUARDD-US: A Pragmatic, Randomized Trial of Genetic Testing for APOL1 and Pharmacogenomic Predictors of Antihypertensive Efficacy in Patients with Hypertension (2022): https://www.sciencedirect.com/science/article/pii/S1551714422001392
• Establishing a Cohort and a Biorepository to Identify Biomarkers for Early Detection of Lung Cancer: The Nashville Lung Cancer Screening Trial Cohort (2021): https://www.atsjournals.org/doi/full/10.1513/AnnalsATS.202004-344OC
• Development of a Lung Nodule Cohort with Integrated Clinical, Molecular and Imaging Biomarkers (2019): https://aacrjournals.org/cancerres/article/79/13_Supplement/3317/635214

Thomas Reese, PharmD, PhD is a board-certified ambulatory care pharmacist and clinical informatician with a strong commitment to patient-oriented research. He was a fellow in the NCI's Multilevel Intervention Training Institute and trained on the National Library of Medicine T15 grant at the University of Utah. Dr. Reese was motivated by clinical practice to understand how clinicians can make better decisions. In this pursuit, he has focused on enhancing the human-computer interaction through interoperable clinical decision support and has led projects on designing and developing integrated information displays for critical care and shared decision-making tools for drug-drug interactions. He is particularly interested in using health information technology to implement evidence-based practice in contextually and theoretically informed ways. Dr. Reese received a career development award from AHRQ to combine clinical decision support with patient reported outcomes to improve treatment for opioid use disorder.